source
- German biotech Immatics eyes pivotal Phase 3 readout after promising uveal melanoma cell therapy resultsImmatics, a German biotech founded 26 years ago, is focusing on cancer immunotherapy. Its lead candidate is an experimental cell therapy targeting uveal melanoma. Early Phase 1 data in 16 patients…
- Hologic acquires Spain’s Reveal Genomics to expand breast cancer genomic testingHologic, a medical‑technology company, announced it will acquire precision‑oncology firm Reveal Genomics, based in Spain. Reveal Genomics develops advanced genomic diagnostic tests, notably the HE…